News

PPI
apitope
cequr
interrad
reneuron
sphere
simbec
verona
medaphor

Proton Partners International Annouces New Cancer Centre In North West

Liverpool, 15th March 2017: Proton Partners International has today announced plans to build a new £35 million cancer treatment centre in Liverpool.

Read more

The cancer centre will be built in the new £1 billion Paddington Village, part of Liverpool’s Knowledge Quarter (KQ).

This will be one of four centres built by Proton Partners International in the UK and will make the company the world’s largest developer of proton beam therapy centres. Proton Partners International is currently building three other UK cancer centres, in Newport, Northumberland and Reading, and is considering further sites.

The oncology centre, which will be known as The Rutherford Cancer Centre North West, will offer radiotherapy, chemotherapy and imaging from 2018, and proton beam therapy will be available in 2019.

Joe Anderson, Mayor of Liverpool, said: “We are delighted KQ Liverpool has been able to attract another prestigious development to Paddington Village.

“Momentum is really beginning to build for KQ Liverpool and we can expect more exciting announcements like Proton Partners International’s, which will further cement its reputation as a world leading hub in medical and life sciences research.”

Mike Moran, chief executive officer of Proton Partners International, said: “I am delighted to announce that our fourth UK centre is to be in my home city of Liverpool.

“Not only will we be bringing the top cancer technology to the North West, but we will be located at heart of what will be a world-class destination for science, innovation, education and technology.

This investment will not only enhance the level of cancer treatment available to patients, but will also bring skilled jobs to the area.”

It is expected The Rutherford Cancer Centres will each be able to treat up to 500 patients a year and treatment will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.

Proton Partners International is also building a genomics research centre at the Life Sciences Accelerator building in Liverpool which will be the first part of a health campus set to surround the £335m new Royal Liverpool Hospital. The genomics programme will support Proton Partners International’s broader research work with the University of Liverpool’s Physics Department.

ENDS

Notes to Editors

Contact details

Sophie Watson, Media House International, 0207 710 0020 orSophie@mediahouse.co.uk

Ramsay Smith, Media House International, 0207 710 0020 orRamsay@mediahouse.co.uk

About The Rutherford Cancer Centres

The Rutherford Cancer Centres are at the forefront of providing innovative cancer care and creating a better future for cancer patients. With its commitment to excellence, the centres will provide an all-encompassing cancer service, delivering world-class imaging, chemotherapy, radiotherapy and proton beam therapy treatment.

Services will be available to patients under medical insurance self-pay patients and patients referred by the NHS.

About Proton Partners International Ltd

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors committed to almost £100m equity finance in the company.

Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.

The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.

For more information on Proton Partners, please visit: http://proton-int.com/

Follow us on twitter @ProtonPartners

About KQ Liverpool

KQ Liverpool is a 450-acre urban innovation district and is home to some of the world’s most influential players in science, health, technology, education, music and the creative and performing arts. With over £1bn of new developments currently underway – and a further £1bn in the pipeline – the plan is to increase the city’s employment figures, improve graduate retention and attraction rates and establish Liverpool at the forefront of the Northern Powerhouse. The unique mix of science, medicine and culture, combined with KQ Liverpool’s stunning architecture and its position at the heart of the city, has already attracted the Royal College of Physicians who have chosen KQ Liverpool as the home for their new Northern Centre of Excellence. The KQ Liverpool team is tasked with defining, creating and promoting the place and occupies the dynamic space between ambition and delivery. We believe that the whole is greater than the sum of its parts, which is why we bring together the city’s key partners to collaborate in a creative environment, allowing us to not only discover and present opportunities but to respond to them quickly. We provide consistent messaging, a single point of contact for investors and businesses and through the ‘power of place’ foster clustering, networking and knowledge transfer. www.KQLiverpool.co.uk

For more information about KQ Liverpool, please contact Michael Doran at Liverpool City Council Newscentre on 0151 233 0074 or 0780 1453918.

Proton partners international announces the rutherford cancer centres

22 February 2017: Proton Partners International has announced today it is to name its clinics The Rutherford Cancer Centres.

Read more

The Rutherford Cancer Centres will offer patients a comprehensive range of cancer treatments and, from 2018, will be the first in the UK to offer high energy proton beam therapy.

The oncology centres have been named to reflect the renowned scientist Ernest Rutherford’s contribution in identifying and naming the proton in 1911.

Three centres are currently under development, in Newport, South Wales, Bomarsund, Northumberland and Reading, Berkshire. The Rutherford Cancer Centre, South Wales is nearing completion and will offer chemotherapy, radiotherapy and imaging via the latest planning and treatment technologies. Positron emission tomography–computed tomography (PET-CT) will be available in the second half of this year and proton beam therapy will be available at the centre from early 2018.

Treatment at The Rutherford Cancer Centres will be available to medically-insured private patients, self-paying patients and patients referred by the NHS.

Professor Gordon McVie, chairman of Proton Partners International, said: “We’re delighted to announce the creation of The Rutherford Cancer Centres.

“Proton Partners International is committed to transforming cancer care in the UK. The Rutherford name is synonymous with a major breakthrough in cancer treatment and therefore we felt that this was a fitting identity for our treatment centres.

“With cancer on the rise, there is a growing need for patients to be offered a holistic and sophisticated level of cancer care.  Patients at The Rutherford Cancer Centres will have access to a wide range of cancer services and a treatment plan will be implemented on an individual basis.”

Mike Moran, chief executive officer of Proton Partners International, said: “We are working with the world’s leading technology partners to ensure that our centres are equipped with the latest cancer technology.

“Our centres will have the capacity to treat 500 unique patients a year. We will also network our centres to ensure the data they will provide can play a significant role in cancer research. We are committed to undertaking a genomics programme which will collate, analyse and distribute data through our research facility at the Life Sciences Accelerator centre in Liverpool.”

Notes to Editors

 Contact details

Sophie Watson, Media House International, 0207 710 0020 or Sophie@mediahouse.co.uk

Ramsay Smith, Media House International, 0207 710 0020 or Ramsay@mediahouse.co.uk

About The Rutherford Cancer Centres

The Rutherford Cancer Centres are at the forefront of providing innovative cancer care and creating a better future for cancer patients. With its commitment to excellence, the centres will provide an all-encompassing cancer service, delivering world-class imaging, chemotherapy, radiotherapy and proton beam therapy treatment.

Services will be available to patients under medical insurance self-pay patients and patients referred by the NHS.

About Proton Partners International Ltd

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors committed to almost £100m equity finance in the company.

Professor Gordon McVie, Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM), is non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.

The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.

For more information on Proton Partners, please visit: http://proton-int.com/

Follow us on twitter @ProtonPartners

Ramsay Smith

Executive Director | Media House International Ltd

t: 0207 710 0020 |​ m:07788 414 856

t: 0141 220 6040 | f: 0141 220 6044

Apitope Announces Positive ATX-MS-1467 Phase IIa Data in Relapsing Multiple Sclerosis

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis.

Read more
 

The Phase IIa, open-label, one arm study evaluated the effects of ATX-MS-1467 in 19 patients with relapsing multiple sclerosis. The investigational product was administered intradermally (ID) every 2 weeks for 20 weeks. Following a dose titration of 50 and 200 μg in the initial 4 weeks of treatment a dose of 800μg was administered fortnightly for a further of 16 weeks.

There were statistically significant reductions in total and new T1 Gadolinium enhancing lesions measured using MRI during treatment as well as a significant reduction in the volume of T1 Gadolinium enhancing lesions. The data also showed a strong trend towards improvement in the Multiple Sclerosis Functional Composite (MSFC) score that is used clinically as an indicator of improvement in disability. There were no treatment related serious adverse events and the adverse event profile was mild.

Dr Keith Martin, Chief Executive Officer of Apitope, commented: “We are delighted with these positive results that confirm both clinical findings in our Phase Ib trial as well as preclinical results showing significant decreases in MRI detected lesions and disability in a standard multiple sclerosis model. We will continue to progress the development of ATX-MS-1467 as a treatment for multiple sclerosis and are currently preparing for a Phase IIb placebo controlled study to demonstrate clinical efficacy.”

Dr Jeremy Chataway, Consultant Neurologist, National Hospital for Neurology and Neurosurgery, London, commenting on the results said: “Having been the Chief Investigator on the previous Phase Ib study, it is pleasing to see these promising confirmatory Phase IIa results where ATX-MS-1467 has shown both an encouraging efficacy and an excellent safety and tolerability profile. While these patients were only treated for 20 weeks, results in a Phase IIb study with a longer treatment period will be interesting.”

The compound had previously completed a Phase I clinical study in six patients with secondary progressive multiple sclerosis (SPMS) and a second Phase I study in 43 relapsing multiple sclerosis patients, assessing safety and biological parameters. The latest results support the further development of ATX-MS-1467 in multiple sclerosis.

For further information:

Apitope

Dr Keith Martin, CEO

Tel: +44 (0)1291 63 55 11

keith.martin@apitope.com

For media enquiries:

Hume Brophy

Conor Griffin, Alexia Faure, Alexander Protsenko

Tel: +44 (0)20 7862 6381

apitope@humebrophy.com

 About Apitope

Apitope is a European biotech company focused on the discovery and development of disease modifying therapies for abnormal immune responses including autoimmune diseases such as, multiple sclerosis, Graves’ disease, and uveitis; and Factor VIII intolerance

Apitope has a patented discovery platform which enables selection of disease-modifying peptide therapies for the target of interest; and has already generated a pipeline of seven programmes in clinical and preclinical development, of which the lead programme in multiple sclerosis is in Phase II. The discovery engine selects Apitopes™ – Antigen Processing Independent epiTOPES. Apitopes are soluble, synthetic peptides from the human sequence which can selectively suppress abnormal immune responses and reinstate the normal immune balance. Stakeholders in the company include Wales Life Sciences Fund, Vesalius Biocapital, LRM, the Wellcome Trust and the US MS charity, Fast Forward.

About ATX-MS-1467

Apitope’s lead product candidate is ATX-MS-1467, a potentially disease-modifying therapy for the treatment of multiple sclerosis, is a novel peptide-based therapeutic identified using Apitope’s proprietary technology platform.

It consists of four short peptides that are derived from myelin basic protein, a key autoantigen in multiple sclerosis. It is designed to induce immunological tolerance of the body’s T cells to key autoantigens thought to be involved in the pathogenesis of multiple sclerosis.

For more information on the Company, please visit: www.apitope.com 

Alexander Protsenko

Consultant

Hume Brophy | 55 King William Street | London EC4R 9AD | UK

DD +44 (0)20 7862 6397 | T +44 (0)20 7862 6481 | M +44 (0)73 9376 5184

alex.protsenko@humebrophy.com

 

Arthurian life sciences statement on reneuron stroke study results

London, 5th December 2016: Arthurian Life Sciences today welcomed the ‘highly encouraging’ findings of a significant clinical trial by ReNeuron, a global leader in the development of cell-based therapeutics.

The PISCES II trial monitored improvement in arm movement as measured by the ARAT sub-test number two.
The aim was to achieve discernible change within three months in two of the 21 patients receiving treatment. Three patients registered improvement over a variety of timescales. 15 patients in the 21-person study had a “clinically significant response” on at least one of the three commonly-used scales for assessing improvements following treatment.

Read more

ReNeuron now intends to apply to the US and European regulatory authorities to commence a randomised, placebo-controlled, pivotal clinical trial in patients who are living with disability post-stroke.

Arthurian Life Sciences manages the Wales Life Sciences Investment Fund which made a substantial investment in ReNeuron and attracted the company to Wales.

Professor Sir Christopher Evans, chairman and founder of Arthurian Life Sciences, said: “We are delighted that ReNeuron has reported such encouraging results from its latest study. The treatment has great potential for patients and the company will go into its next trial with confidence. The results of the PISCES II trial are also a real boost for life sciences in Wales.

“These strong Pisces II results follow on from all of the positive safety and efficacy data accumulated over the last three years from the Pisces 1 study. “

Proposed Placing to raise c. £44.7 million (US$63.3 million) and Notice of General Meeting

Capitalised terms in this announcement have the same meaning as in the Circular being published in

conjunction with the proposed placing (unless otherwise indicated) and are also defined below.

17 June 2016, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that it has successfully secured funding commitments to raise gross proceeds of c. £44.7 million (US$63.3 million), through a conditional placing (the “Placing”) with new and existing investors, including a number of specialist US, UK and European healthcare funds. The Placing was significantly oversubscribed.

The net proceeds of the Placing are expected to fund RPL554 through a Phase 2b clinical trial in chronic obstructive pulmonary disease (COPD) patients and additional Phase 2 studies in both COPD and cystic fibrosis.

MTS Securities, LLC is acting as the US placement agent and N+1 Singer is acting as the UK broker and nominated adviser in connection with the Placing. The Placing is not being underwritten.

Read more

Highlights

  • The Placing will raise gross proceeds of c. £44.7 million (US$63.3 million) through the issue of 1,555,796,345 Units at a price of 2.873 pence per Unit (each comprising one Placing Share and one Warrant)
  • The net proceeds of the Placing will predominantly be used to progress RPL554 through a Phase 2b clinical trial in COPD patients, and to fund additional clinical Phase 2 studies in COPD and cystic fibrosis as well as further supportive pre-clinical work
  • The funding enables the Company to materially advance the development of RPL554 and build on the significant progress made to date with the revised formulation
  • The cornerstone investors in the Placing are specialist healthcare focused funds Vivo Capital, OrbiMed and Edmond de Rothschild Investment Partners
  • Other new investors include New Enterprise Associates, Novo A/S, Abingworth and

Aisling Capital with participation of existing investors including Arix Bioscience, Hargreave Hale and Polar Capital

  • The Placing Price represents the average closing mid-market price of an Ordinary Share during the five trading days to 15 June 2016, being the last practicable date prior to investors signing their binding Placing commitments
  • Each Warrant will be exercisable into 0.4 of a Warrant Share, at an exercise price per Warrant Share of 3.4476 pence, being 120 per cent. of the Issue Price
  • On or shortly after Admission, representatives from certain of the investors will join the Board as non-executive directors
  • The Company has undertaken to use commercially reasonable efforts to procure a listing on NASDAQ and raise a further tranche of funding in the future

The Placing is conditional upon, amongst other things, approval by existing shareholders at a general meeting to be held at 11.00 a.m. on 22 July 2016 at the offices of Shakespeare Martineau LLP at Allianz House, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR (the “General Meeting”). Admission of the Placing Shares to trading on AIM is expected to take place on 29 July 2016.

Jan-Anders Karlsson, CEO of Verona Pharma, commented:

“We have made significant clinical progress with our first-in-class drug RPL554. This drug has shown the potential to become an important novel and complementary treatment option for patients with COPD, a debilitating and progressive disease that impacts about 65 million people worldwide and is still among the four leading causes of death globally.

“The funds raised from the Placing will allow the Company to focus on conducting a comprehensive Phase 2b clinical trial programme for nebulised RPL554 as a potential treatment for patients with COPD. We will also explore in the clinic for the first time the use of RPL554 as a novel treatment for cystic fibrosis expanding the potential of the drug into another respiratory disease where there remains a significant unmet need. This follows on from the compelling data we have generated in translational, preclinical models of this disease.”

David Ebsworth, Non-Executive Chairman of Verona Pharma added:

“The Board would like to thank both the proposed new and our existing shareholders for their support. Indeed, this powerful syndicate of highly experienced bioscience investors have conducted significant due diligence in the product ahead of investing in the proposed Placing announced today, which we believe further attests to the potential value of RPL554.

“This funding will enable us to progress RPL554 through significant value inflection points. The strength of the data package for the product generated to date gives us confidence that a substantial Placing provides the optimal opportunity to retain maximum value in the Company without compromising our future strategic options.

“A subsequent listing of ADSs on NASDAQ as part of a US IPO for Verona Pharma is a natural evolution in our corporate strategy to focus on the US market opportunity, with its broadly accepted use of nebulisers in the treatment of patients with COPD. It will also allow the Company easier access to a larger pool of investors in the US who have a deep understanding of the healthcare market in which Verona Pharma operates.”

The Company’s lead drug, RPL554, is a dual phosphodiesterase PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties that has the potential to become a novel treatment for patients with obstructive lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis and potentially asthma. Furthermore, based on data generated to date, Verona Pharma believes RPL554 can provide relevant clinical and health economic benefits in a commercial setting.

A circular to Shareholders containing, amongst other things, the notice of the General Meeting (the “Circular”) will be published by the Company today and posted to Shareholders. An extract from the Circular is set out below. Copies of the Circular will be available at the Company’s website: www.veronapharma.com.

This announcement should be read in conjunction with the Circular in its entirety, which contains further details on the terms of the Placing and related matters.

CeQur establishes Wales subsidiary

Arthurian Life Sciences investment helps bring to market world’s first three-day simple insulin infusion device for type 2 diabetes.

LUCERNE, Switzerland, Sept. 1, 2015 /PRNewswire/ — CeQur SA, a leader in simple insulin infusion for people with diabetes, announced that the Company plans to conduct clinical studies and has established a subsidiary in Wales following a major investment co-led by Arthurian Life Sciences.

“CeQur aligns with our vision to invest in companies that contribute to a successful, vibrant, growing, and socially meaningful Life Sciences sector in Wales. We were delighted to again work closely with Neil Woodford to make a significant investment into a company that will become a very important part of the Welsh life sciences ecosystem. This is the third transaction of over $100 million we have led or co-led in the last three months from the Welsh Life Sciences Fund,” said Professor Chris Evans OBE, chairman, Arthurian Life Sciences.

CeQur recently announced a $100 million C round of financing to support further clinical and regulatory activities, manufacturing scale-up and commercial operations for a planned European and US 2016 launch of the Company’s novel, three-day insulin infusion device, PaQ®.

Read more

PaQ is a simple patch-like insulin infusion device that has the potential to offer an alternative to insulin injections for people with type 2 diabetes, a worldwide market estimated to be worth approximately $6 billion.[1]

Wales-based Arthurian Life Sciences Ltd. (ALS) co-led the round with Woodford Investment Management LLP. Brenig Preest, investment manager of Arthurian Life Sciences, will serve as a member of the CeQur Board of Directors. Existing investors including Endeavour Vision, Schroder & Co. Banque SA and VI Partners participated in the round.

CeQur’s CEO, Doug Lawrence, said: “We are very excited to be working with Arthurian Life Sciences and Woodford Investment Management, who clearly saw the potential of PaQ and are as enthusiastic as we are about the commercial opportunity.”

CeQur is preparing to launch its fully optimized, second-generation PaQ and has established a UK subsidiary in Wales. One of the Company’s first activities in Wales will be a clinical study in collaboration with University of Swansea scheduled to begin enrollment in 2016.

“Knowing first-hand the challenges people with type 2 diabetes face in managing daily insulin injections, we are excited to be part of the ongoing clinical program evaluating insulin delivery with PaQ,” said Professor Steve Bain, professor of medicine, University of Swansea, who will serve as principal investigator for the Swansea trial site. “If insulin delivery is less burdensome, glycaemic control should improve and subsequently so should long-term health.”

PaQ is a simple and cost-effective device that helps people with type 2 diabetes overcome the known barriers to insulin therapy. “We are delighted that our patients who face the challenges of diabetes will be the first in Wales to try this new and exciting device, which should make their lives easier,” said Hamish Laing, medical director of the ABM University Health Board.

About CeQur®
CeQur is dedicated to developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company is headquartered in Lucerne, Switzerland, with operations in Marlborough, Massachusetts and Nordborg, Denmark.
CeQur was established in January 2008. The company is chaired by 34-year J&J veteran Eric Milledge and led by a team of highly experienced executives with backgrounds from relevant companies including Becton Dickinson & Company, J&J, Novo Nordisk, Abbott, Roche, and Smith & Nephew. The Company’s fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections. More information can be found at www.cequr.com.

About Woodford Investment Management
Woodford Investment Management LLP is a fast-growing asset management company built on a founding philosophy of transparency and simplicity. Launched in May 2014, the company has more than £12bn assets under management. Further information can be found at https://woodfordfunds.com

About Arthurian Life Sciences
Founded by renowned life sciences entrepreneur Professor Sir Chris Evans, Arthurian has an investment team with more than 200 years combined experience, having raised over USD 11 billion of investment funds and USD 9.4 billion of co-investment. Arthurian is a specialist in the life sciences sector. It is discretionary fund manager of the Wales Life Sciences Investment Fund LP (the “Fund”). The Fund is a strategic investment fund whose cornerstone investor is the Welsh Government. It invests globally across the life sciences sector where those investments bring economic benefit to the life sciences sector in Wales.

About Endeavour Vision Ltd.
Endeavour is an internationally recognized investor in innovative technologies, in particular in medical technologies, with more than 60 investments made globally. The team combines successful investment professionals and world-class industry veterans with extensive experience in the medical device industry in the US, Europe and Asia. Endeavour Vision focuses on companies with global ambitions in medical technology and digital health sectors in Europe and the US, helping them to accelerate their global growth and market leadership.
For more information about Endeavour and its portfolio, please visit www.endeavourvision.com.
About Schroders
Schroders is a global asset management company with CHF 455.6 billion assets under management (as of 30 June, 2015). The asset manager’s clients are major financial institutions including pension funds, banks and insurance companies, local and public authorities, governments, charities, high-net-worth individuals and retail investors. Schroders has developed under stable ownership for over 210 years.
Schroders has been active in Switzerland since 1967. With CHF 26.4 billion of assets under management and around 260 employees, Switzerland is Schroders’ second most important market outside the UK. The Schroders Private Equity department working from the Geneva office has been active since 2007, and currently manages a portfolio of eight direct investments across sectors and geographies.

About VI Partners
VI Partners is a leading Swiss venture capital firm that invests in university spin-off’s as well as in promising companies in the healthcare and ICT sectors. Over the last decade, more than 30 successful investments were made in Switzerland and surrounding regions to develop promising technology-based ideas for products and services into successful businesses. VI Partners team combines seasoned investment professionals and a worldwide recognized network of experts from the industry, financial and consulting sectors.

For more information please contact:
Switzerland Media Contact:
Fergus Dullaghan
41 (0) 79 101 88 92
fergus@charlescannon.com
UK Media and IR Contacts:
Mary-Jane Elliott/Lindsey Neville
Consilium Strategic Communications
+44 20 3709 5707
Cequr@consilium-comms.com
Lynsey Conway
+44 1428 481705
email@lynseyconway.co.uk
US Media Contact:
Michele Parisi
1-925-429-1850
mparisi@forwardhealthinc.com
[1] International Diabetes Foundation, IMS, Health Advances and CeQur management estimates
SOURCE CeQur SA

RELATED LINKS

http://www.cequrcorp.com

Share via Twitter

Share via LinkedIn

Proton partners international brings proton beam therapy to England

30th July 2015: Proton Partners International Limited today unveiled the site of the first Proton Beam Therapy cancer treatment centre to be built in England.

The centre will be the second to be built by Proton Partners International in the UK. It will be situated on the Earth Balance wellness suite in Bomarsund, Northumberland, and will operational by early 2017.

Earlier this month Proton Partners announced that it had already started work on its first site in Newport, Wales. The third centre will be in London. Each centre will be able to treat up to 700 patients annually.

Read more

Gordon McVie, Chairman of Proton Partners International Ltd, said: “Our goal is to herald a new era of cancer care provision in the UK, bringing the first high energy Proton Beam Therapy centres to the UK and therefore unveiling our second site today marks another significant milestone.

“It is estimated that around 10% of patients who receive radiotherapy would be better treated by Proton Beam Therapy. Across the world Proton Beam Therapy has been shown to deliver significant results for patients, especially in lowering side effects. The sooner we can start treating patients with Proton Beam Therapy in the UK the better.”

Speaking at the launch, Councillor Grant Davey, Leader of Northumberland County Council, said: “We are delighted Northumberland has been chosen as the first place in England to be able to provide high energy Proton Beam Therapy. This is not only good news for the county – it will provide a great economic boost to the whole region and highlight our commitment as a place to invest for the future.”

Mike Moran, Chief Executive Officer of Proton Partners International Ltd., added: “The new centres to be opened by Proton Partners will not just benefit private patients, but also hope to treat NHS patients in need of more highly specialised cancer care. We are working with global leaders in Proton Beam Therapy – our centres will be equipped with the best technology there is.”

The work is part of a new programme of developments by the Earth Balance charity which is opening the wellness site to help meet the needs of current and future generations.

Chair of Earth Balance, Alan Rutherford said: “We are delighted that Proton Partners International are coming to the site and we are working hard with local healthcare partners, energy partners, health and wellbeing partners and the local community to ensure that the training and care opportunities are meeting local needs.”

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, has been selected to install its single-room proton therapy system, Proteus®ONE.

Philips has been appointed to deliver software and technology tools including Philips’ Pinnacle Treatment Planning which delivers an intuitive planning environment that simplifies workflow. Philips will also provide big bore CT scanners at each centre and a PET CT in the Newport centre.

ENDS

Further information:

Contact

Ramsay Smith, Media House 07788 414856 ramsay@mediahouse.co.uk

Sophie Watson, Media House 0207 710 0020 / 07554 005794 sophie@mediahouse.co.uk

About Proton Partners International Limited

Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, which partners the Italian Hadron Centre in Pavia, has been appointed chairman and Professor Karol Sikora is chief medical adviser to the company.

For more information on Proton Partners, please visit: http://proton-int.com/

About Proton Beam Therapy

Proton beam therapy is a highly-targeted type of radiotherapy that can treat hard-to-reach cancers, such as spinal tumours (chordomas), with a lower risk of damaging the surrounding tissue and causing side effects.

Proton Partners International Chief Executive Officer Mike Moran (centre) and Chairman of Earth Balance Alan Rutherford (left) with Northumberland County Council Leader Cllr Grant Davey at the site of the new proton beam therapy centre in Northumberland.

The site of the new pioneering proton beam therapy centre in Bomarsund, Northumberland which will be constructed and operational by 2017.

Share via Twitter

Share via LinkedIn

Proton partners international chosen to develop and operate UAE’s first proton beam therapy centre

July 17th 2015: Proton Partners International Ltd has been chosen to provide the United Arab Emirates with its first Proton Beam Therapy centre.

Proving that they are not only leading the way for Proton Beam Therapy in the UK but also abroad, Proton Partners has been selected to develop and operate the Abu Dhabi Proton Centre (ADPC) in Abu Dhabi with SBK Holding LLC and Albans Partners General Trading LLC.


Read more

Mike Moran MBE, CEO of Proton Partners International Ltd, said: “I am delighted to be invited to the UAE to support the development of the Abu Dhabi Proton Centre (ADPC).

“Proton Partners International is the United Kingdom’s leading developer of Proton Beam Therapy facilities having recently announced the development of three centres across the UK. We work with world leading technology partners such as Philips, IBA, ORCA and MEI Healthcare and I am thrilled that they will also support us in the development of the ADPC.

“By bringing Proton Beam Therapy to the people of UAE, His Highness Dr. Sheikh Sultan Bin Khalifa Al Nahyan has shown a vision for the future of healthcare in the country and I very much look forward to supporting his aim of delivering the most advanced cancer treatments to the people of the UAE.”

Professor Karol Sikora, Chief Medical Officer of Proton Partners International, said: “It is fantastic that His Highness’ foresight will lead to the first installation of sophisticated proton delivery technology in the Middle East. I am confident that by creating a global network of proton centres connecting leading institutes in Britain with Abu Dhabi is the best way forward.

“Proton therapy is suitable for around 10% of patients receiving conventional radiotherapy and delivers a much more precise dose distribution, sparing normal tissue and so serious long term toxicity. We are confident that with the skills and enthusiasm we’ve seen in Abu Dhabi, we can deliver this project within the next two years.  Cancer incidence is rising dramatically globally and more innovation is needed to deal with this disease. We envisage this development will put the UAE in the frontline of cancer treatment and research.”

Gordon Baltzer, Chairman of the MEI Healthcare Group, said: “Our organisation is truly excited about this opportunity to bring innovative healthcare technology and expertise to patients in the United Arab Emirates.

“The creation of this comprehensive cancer center including innovative proton therapy capability, will ensure access to world class oncology services in the UAE.”

David Knott, Chief Executive Officer for the MEI Healthcare Group, added:  “This innovative and proven team of healthcare partners possess the required expertise and capability to ensure the successful development, construction, and operation of this state-of-the-art oncology program.”

SBK Holding LLC is the Holding Company of His Highness Dr. Sheikh Sultan Bin Khalifa Bin Zayed Al Nahyan, Advisor to the President of the United Arab Emirates, the eldest son of His Highness Sheikh Khalifa Bin Zayed Al Nahyan, President of the United Arab Emirates, Supreme Commander of the UAE Armed Forces, and Ruler of Abu Dhabi.

SBK Holding has a range of companies that serve a broad cross-section of industries not only in the Gulf region but also globally. SBK Holding employs 10,000 employees in the UAE and with its substantial international investments the company has a workforce that reaches all corners of the world.

ENDS

Further information:
Sophie Watson / Gary McQueen
Media House International Ltd.
0207 710 0020 / 0141 220 6040

About Proton Therapy
Proton Therapy is considered the most advanced and targeted cancer radiotherapy treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life. Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 18 proton therapy centers currently in operation and 19 additional centers under development.

While proton therapy today represents less than 1% of radiotherapy treatments, studies estimate that more than 17% of patients treated by radiotherapy would benefit from being treated by this technique.

About Proton Partners International Limited
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, has been appointed chairman, Professor Karol Sikora is Chief Medical Advisor and, one of the Founders, Mike Moran MBE has been appointed as the Chief Executive Officer.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems.  In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets.  IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

About Philips
Royal Philips is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries.

The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About MEI Healthcare Group
MEI Healthcare Group is a U.S. based healthcare strategy and development company that provides vertically integrated solutions to the global healthcare community. MEI has more than 40 years of experience in the turn-key planning, development, financing and commercialization of healthcare strategies across a variety of service lines.   MEI’s service portfolio includes project development, equipment selection, financial modelling, advisory and consultative services, and facility management services.  MEI Healthcare Group is led by Gordon Baltzer, Chairman and David Knott, Chief Executive Officer.

Share via Twitter

Share via LinkedIn

Reneuron Success Boosts Wales Life Sciences Fund

London, Friday 10 July 2015 – Professor Sir Christopher Evans, chairman of Arthurian Life Sciences Ltd, said today that it is ‘pivotal’ that Wales continues to aggressively develop its life sciences sector following the ‘hugely encouraging’ fundraising for ReNeuron Group plc.

ReNeuron Group plc, a leading UK-based clinical-stage cell therapy company, today announced that it had raised £68.4million ($100m) through a conditional placing with new and existing investors in the UK, which marks a significant step towards improving the therapeutic programmes on offer.

Read more

 

Arthurian were the first of the original investors in ReNeuron Group plc, committing a further £5million to help lead the latest and significant investment round of £68.4million. Other existing investors – Woodford, Aviva and Abingworth – also committed substantial amounts to the fundraise. Several new institutional investors from the UK and USA also joined in this landmark fundraise for the company.

Sir Chris Evans said: “The ReNeuron fundraising has been very successful and hugely encouraging, not just for the Company but for life sciences in Wales as well.
“Wales has made some very significant strides in developing its life sciences sector through the establishment of the Wales Life Sciences Fund and it is pivotal that Wales continues to keep aggressively pursuing these opportunities.

“This is a momentous achievement for ReNeuron – this fundraise underpins one of the world’s most exciting novel stem-cell therapeutic portfolios. These new funds will be used to further progress ReNeuron’s CTX therapies in trials for Stroke and Critical Limb Ischaemia, to initiate new trials with the unique hRPC stem cell formulations for Retinal Blindness and to rapidly progress the Company’s new breakthrough platform technology in Exosome Nanomedicines for Cancer and other future applications.

“It is a hugely significant development for the future of cell-based therapies across the globe. The future looks bright and very exciting for this world leading stem-cell company and I’m delighted to have been associated with it from the very beginning.”

Sir Chris’ Arthurian Welsh Life Sciences Fund has shot up in value, going from strength to strength in under 15 months from a standing start as significant product announcements are made and new investments are sealed in an ever expanding pipeline of very exciting biotech and healthcare businesses.

The Fund is about to conclude two more investments in July, establishing a portfolio of 10 companies valued over £600million and having attracted in excess of £250million new co- investment in under 15 months. The Fund is running at a 48% IRR and the Team are evaluating several future transactions from a deal flow pool in excess of 450 new life sciences businesses from around the world.

ENDS
Notes to Editors:
Media contact
Ramsay Smith at Media House International on 020 7710 0020 or ramsay@mediahouse.co.uk
Sophie Watson at Media House International on 020 7710 0020 or sophie@mediahouse.co.uk

About Arthurian Life Sciences
Arthurian Life Sciences Ltd was specifically established by Europe’s leading biotech entrepreneur Professor Sir Chris Evans OBE to apply to provide management services to the Wales Life Sciences Investment Fund. Arthurian boasts a vastly experienced, internationally renowned Board of Directors and investment team comprised of individuals from the public and private Life Sciences sector and from the world of international fund management, business, commerce and government. The Arthurian team currently manages, advises and consults to billions of pounds of assets in private equity and traditional investments.

Share via Twitter

Share via LinkedIn